DDInter108 DDInter1658
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Apixaban {u} (Compound) binds {v} (Gene) CYP2C8
Apixaban {u} (Compound) causes {v} (Side Effect) Incision site haemorrhage
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Apixaban (Compound) binds CYP2C8 (Gene)
Apixaban (Compound) causes Incision site haemorrhage (Side Effect)
Apixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Apixaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Apixaban may lead to a major life threatening interaction when taken with Desirudin
Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine